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As the population grows older each year, age-related macular degeneration (AMD) is becoming the
leading eye disease resulting in blindness. Although some drugs are available for the treatment of wet
AMD, no drug is currently available for dry AMD. Actual research is taking place to invent novel drug for
the treatment of dry AMD and the hurdles of the R&D are reviewed. Literature search and review were
conducted to identify various ideas to treat dry AMD and to overcome the difﬁculties of developing
clinical end points for developing the new drugs. Some promising drug candidates had been identiﬁed
and clinical end points of drug efﬁcacy determination had been collected. With the proof of new concepts
and clinical end points available, the hope is high to expect some new novel drugs be put in the market
sometime in the future.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Age-related macular degeneration (AMD) is a debilitating
disease on central vision in patients over 50 years old.1,2 It was ﬁrst
described in the medical literature as a symmetrical central cho-
rioretinal disease occurring in senile individuals.3 It was not until
1980 that AMD was regenerated to be a signiﬁcant cause of blind-
ness in the United States.4 Even though the prevalence of AMD is
highest among Caucasians in Western countries, the prevalence
among Asians is equally as high as Caucasians in AMDdevelopment5
(Wong et al, 2006). In 2004, the World Health Organization esti-
mated that there are 14 million individuals worldwide suffering
from blindness or are severely visually impaired due to AMD. As the
population in the Western world is growing older, the incidence of
losing the ability to read and to drive due to AMD is becoming
increasingly apparent.6 An analysis in 2004 reported that among
Americans over the age of 40 years, AMD and/or geographic atrophy
were present in at least one eye in 1.5% of the population.7 By the
year 2020, there may be a 50% increase in the incidence of AMD.8
predicted that as a result of the increasing prevalence of AMD, the
number of blind people in the United States could increase by as
much as 70% by 2020. Given the enormous impact of AMD on the
aging population, much public attention and research has been
focused on this condition in the past decade.alth Science Center, 303 Rey-
A.
e Ophthalmologic Society of TaiwaAMD initially occurs in a “dry” form with pathological changes
in the retinal pigment epithelium (RPE) and drusen accumulation
and can progress to geographic atrophy (90%) and/or the “wet”
form of AMD (10%) with choroidal neovascularization (CNV).6 The
breakdown of Bruch’s membrane under RPE serves as an
entrance for new and immature choroid vessels to grow into the
subretinal space that leads to the formation of CNV.6,9e11 CNV can
leak ﬂuid and hemorrhage in the subretinal space resulting in
blurry vision, visual distortion and sudden loss of vision.12 If left
untreated, these can progress to form an organized ﬁbrous scar,
known as a disciform scar, which results in irreversible central
vision loss.
2. Etiology and pathogenesis of dry AMD
Drusen is a typical clinicopathologic entity in dry AMD, which is
caused by the changes of RPE and Bruch’s membrane (BRM). Dru-
sen is deposited in between the basement membrane of RPE and
BRM or external to BRM.13 The prevalence and severity of drusen
formation in the eyes are linearly related to the progression of AMD.
Oxidative stress has long been linked to age-related degenerative
diseases and is implicated in the pathogenesis of AMD. An impor-
tant source of oxidative damage is likely to be the photoreactive
pigments that progressively accumulate and constitute the lip-
ofuscin of RPE cells.14,15
Similar to drusen, basal laminar deposit (BLD) is another typical
sign of AMD development and is led by extracellular deposit. BLD
is located between the cell membrane of RPE and its basement
membrane.16,17 The pathogenesis of BLD could be enhanced byn. Published by Elsevier Taiwan LLC. All rights reserved.
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in BRM is often associated with vascular endothelial growth factor
(VEGF) expression and ultimate development of CNV in wet
AMD.18
Inﬂammation and a compromised immune system are also
attained in the pathogenesis of dry AMD. As a result, anti-
inﬂammatory agents such as steroids are frequently used for the
treatment of dry AMD. More speciﬁcally, complement components
such as C3 and C5 are constituents of drusen in AMD patients.1
Others, such as interleukin-1, interleukin-6 and tumor necrosis
factor, are also implicated in the development of dry AMD. Thus,
interleukin-1 blockers have also been used in dry AMD animal
models.
In addition to age, high-fat diet, light oxidation and inﬂamma-
tion, smoke, alcohol and gene factors are also frequently ques-
tioned. Epidemiologic studies have indicated that cigarette smoke
is the single greatest environmental risk factor for both dry and wet
AMD.19 Mice experiments with inhaled cigarette smoke resulted in
the formation of RPE deposits, thickening of BRM and accumulation
of deposits, within the BRM membrane.20 In another experiment
mice were fed with nicotine in drinking water, and the results
showed that nicotine increased the size and severity of experi-
mental CNV formation.21
The inﬂuence of alcohol on the development of CNV inwet AMD
was studied by.22 The results showed that the activity of fatty acid
ethyl ester synthase activity increased 4-fold in the choroid of
alcohol-treated rats compared with controls. Furthermore, the
amount of ethylesters produced in the choroid was 10-fold higher
in alcohol-fed rats than controls. The size of CNV formation induced
by laser treatment increased by 28% due to alcohol treatment.
In addition to environmental factors, genes also play an
important role in the development of dry AMD. Thus, some animal
models used for AMD studies include transgenic mice treated with
blueegreen light.23
There are some diseases which are similar to AMD. They include
Stargardt macular dystrophy (STGD) and Sorsby’s fundus dystrophy
(SFD). STGD is characterized as dry AMD by accumulation of high
level of lipofuscin in the RPE. It precedes to degeneration of
photocells in the macular and atrophy of RPE.24,25 SFD is a rare
autosomal dominant disorder that results in degeneration of the
macular region, which leads to rapid loss of central vision similar to
wet AMD.26
Most importantly, the choroidal blood ﬂow of dry AMD and
STGD is compromised and signiﬁcantly lower than normal
eyes.27,28 As a result, all metabolic wastes produced from oxidation,
inﬂammation, aging, complement components, cytokines, cigarette
smoke, nicotine, high lipid, and alcohol, etc., are accumulated in
RPE cells and BRM which trigger dry AMD and eventually lead to
wet AMD or geographic atrophy. By contrast, nutrient supply to
BRM, RPE, and photocells at the macula are markedly reduced
which facilitate the worsening of dry AMD.293. Treatment of dry AMD
Treatment of AMD was originally focused on wet AMD, and dry
AMDwas left untreated because no effective method was available.
Physical therapy of wet AMD includes but is not limited to laser
photocoagulation,30e33 transpupilary thermotherapy,34 radio-
therapy.35 Unfortunately, none of these were efﬁcacious and all
were receded to second-line choice of treatment at present when
pharmacological therapy becomes available.
Because CNV formation is the major source of wet AMD devel-
opment, early research for wet AMD treatment has been focused on
antiangiogenesis similar to cancer treatment. These agents includesteroids such as triamcinolone and anecortave acetate36e38
thalidomide,1 and interferon.35
Drugs which can change the construction of the extracellular
matrix or change the balance of matrix metalloproteinases and
tissue inhibitors ofmetalloproteinasesmay also have an effect on the
angiogenesis process.39 These drugs are called extracellular matrix
modiﬁers and are still in the experimental stage of development.
Gene therapy by using subretinal injection of adenoviral or
adeno-associated viral vectors has been used to transform the RPE
into a component for sustained local delivery of a drug or a gene
in experimental CNV animals.1,2 These are drugs of the future for
wet AMD.
Although fruitful progress has been made in the treatment of
wet AMD, the treatment of dry AMD is still sparse. Currently, there
is no single drug available for the treatment of dry AMD. As 90% of
the AMD patient population is in the dry stage, currently there is
active research being carried out at different stages of research and
development.15
Most research and development of dry AMD is concentrated on
the prevention of metabolic waste productionwith limited success,
mainly because the production of metabolic wastes come from
numerous sources, including oxidation, aging, complement
components, cytokines, inﬂammations, etc. Thus, a complete inhi-
bition of one branch of all pathogens can suppress the progression
of dry AMD at only around 20% at best, which is classiﬁed as
borderline efﬁcacy only. In addition, metabolic wastes are normal
products of physiological procedures of the body and complete
inhibition of normal metabolism could result in other various
pathological side effects. Furthermore, visual acuity does not
change signiﬁcantly during the progression of dry AMD; thus,
selection of proper endpoints to evaluate drug efﬁcacy in clinical
trials are very difﬁcult, if not impossible.
Antioxidants are agents that are studied most extensively.
Lutein and zeaxanthin are two major carotenoids in the human
macula and retina.40 They are deposited at an up to 5-fold higher
content in the macular region compared with the peripheral retina.
Owing to the antioxidant properties of carotenoids, lutein and
zeaxanthin are considered to have the ability to protect and/or
delay the progression of dry AMD.
The AREDS (Age-Related Eye Disease Study) report (2001)
described that food supplements that contain carotenoids, antiox-
idants vitamins A, C, and E, plus minerals, such as zinc, showed
a 25% decrease in the rate of progression to aggressive AMD among
high risk patients. The ﬁndings of the LAST (Lutein Antioxidant
Supplementation Trial41; report also support a possible therapeutic
role of lutein in AMD treatment. However, critical evidence of
therapeutic efﬁcacy has not been established.
A novel idea to solve the problem has recently been developed
by Chiou in the Texas A&MHealth Science Center. The idea is based
on the risk factor of dry AMD as a reduction of choroidal blood
ﬂow,27,28,42 which lead to the accumulation of all waste products
regardless of where they come from, including aging, oxidation,
inﬂammation, complement components, cytokines, etc. Thus,
instead of solving problems individually by using inhibiting/
blocking agents of aging, oxidation, inﬂammation, complement
components and cytokines, all waste products will be eliminated
by choroidal circulation. Further nutrients will be replenished to
BRM, RPE, and photocells via improved choroidal circulation in the
macula to improve vision.
Numerous agents that can increase choroidal blood ﬂow in
rabbit eyes have been tested in dry AMD animal models. Among
them, some were found to be rather efﬁcacious in inhibiting the
development of dry AMD. They include, but are not limited to,
hydralazine,43e45 tetramethylpyrazine,46e48 ﬂavone,49,50 nar-
ingenin,11,51 apigenin,52 interleukin-1 blockers,53 and D-timolol.54
G.C.Y. Chiou / Taiwan Journal of Ophthalmology 1 (2011) 2e54Reduction in choroidal blood ﬂow causes deposition of extra-
cellular proteins, lipids, and metabolic wastes in the form of basal
deposits within BRM and of drusen in between BRM and RPE. The
progressive deposition of lipid in BRM results in the degeneration
of elastin and collagen, and ultimately calciﬁcation. The combina-
tion of elevated choriocapillaris pressure, expansion of VEGF, and
break in calciﬁed BRM causes development of CNV and wet AMD.
Vasoactive agents which can facilitate choroidal blood ﬂow are
believed to prevent the progression of dry AMD and are the major
focus of current research.15
4. Clinical protocols for anti-dry AMD drug studies
There are at least two major obstacles which hinder the devel-
opment of drugs for the treatment of dry AMD. First, a long time
period is required to observe progression of the disease,55,56 which
discourages researchers as well as investors to become involved.
Second, the clinical endpoints to show drug efﬁcacy other than
visual acuity are difﬁcult to determine and are not yet approved by
the Food and Drug Administration (FDA). There are several prom-
ising methods under consideration and if approved by the FDA, they
can facilitate drug evaluation and development in the future.57,58
Dry AMD is a unique chronic disease whereby visual acuity does
not change much during the early stage of disease progression. Its
change does not match the worsening of visual acuity until the late
stage of the disease. Consequently, the efﬁcacy of drug actions to
treat dry AMD is impossible to assess, based on the changes of
visual acuity. This is very different from the assessment of wet AMD
drug actions, as the progression of wet AMD is parallel to the loss of
visual acuity. Prolongation of dark adaptation is closely correlated
to the severity of AMD.59e61 Dark adaptation is strongly impacted
in AMD long before there is any signiﬁcant loss of visual acuity.60
Thus, measurement of dark adaptation is one of the feasible ways
to measure drug efﬁcacy for the treatment of dry AMD. The
commercially available prototype dark adaptometer (AdaptRx,
Apeliotus Technologies, Inc., Atlanta, GA, USA) is now available.
Accumulation of the number and size of drusen is another
parameter used to measure the progression of dry AM. Because the
change in drusen deposits is very slow and difﬁcult to note
subjectively, Matched Flicker (EyeIC.com) has been developed to
record the changes objectively and precisely. Basically, the precise
high-tech use in space science to record minute changes occurring
in the sky at any time period has been applied to measure the
changes of drusen occurring in the fundus of the same eye. Basi-
cally, two retinal images of the same eye from virtually any source
can be loaded into Matched Flicker and the changes can be brought
to life and observed as easy-to-detect motion. Because very minute
changes in drusen accumulation can be detected with the machine
precisely and objectively, it shortens the time to detect changes in
drusen deposit compared with the inaccurate subjective observa-
tion with the naked eye in the past. As a result, the clinical study of
drug efﬁcacy in slowing down the rate of drusen accumulation can
be easily accomplished.
As indicated previously, the change of visual acuity, although
most important, is minute and difﬁcult to measure during early and
intermediate stages of dry AMD. However, it is the only measure-
ment approved by the FDA for the study of drug efﬁcacy during late
stage/wet stage of AMD. A useful tool for determining patients’
vision-related function has been developed62 to allow the
improved sensitivity for detection of even a slight change in visual
acuity in the stage of early and intermediate stages of dry AMD. The
device is called NEI VFQ-25 (National Eye Institute Visual Function
Questionaire-25) which is responsive to changes in patients’ visual
acuity and is able to differentiate between patients who are
responders and nonresponders.Although NEI VFQ-25 measures patients’ subjective evaluation
of their visual function and how impairment in vision affects their
lives, it is reliable, valid, and responsive compared with the stan-
dard measure of vision used in clinical trials such as BCVA (Best
Corrected Visual Activity) using standardized ETDRS (Early Treat-
ment of Diabetic Retinopathy Study) vision protocols.62 The NEI
VFQ-25 showed a large separation between the groups with
improved BCVA (gained >15 letters), stable BCVA (gain or lost 15
<letters), and worse BCVA (lost 15 letters). It may also provide
a more broad assessment of the visual function on lifestyle- and
vision-dependent activities than BCVA alone. On average, the 25-
letter or better improvement in BCVA corresponds to an increase
in the NEI VFQ-25 score of 8.2 in the MARINA Trial (Minimally
Classic/Occult Trial of Anti-VEGF Antibody Ranibizumab in the
Treatment of Neovascular AMD).
Although not all dry AMDwould develop into wet AMD,10e15%
of dry AMD would eventually be converted into wet AMD. Thus,
prevention of dry AMD to be converted into wet AMD is also
a measurement of drug action to suppress the progression of dry to
wet AMD. As only 10e15% of dry AMDwould be converted into wet
AMD, a large number of patients are needed to study the difference
in drug treatment. Brieﬂy, ideal clinical endpoints are urgently
needed for the measurement of the efﬁcacy of new drugs for the
treatment of dry AMD. There are at least four methods under
consideration by the FDA. If approved, it can shorten the
measurement of drug efﬁcacy to save time, effort, and funds.
5. Investigative drugs under development
There are numerous drugs under development at various stages.
Somewere discontinued as theywere found to be ineffective. Those
which are still under development include, but are not limited to,
MC1101 (MacuClear) to improve choroidal blood circulation to
excrete metabolic wastes from, and provide nutrients to, RPE, BRM,
and photocells; OT-551 (Othera) as an antioxidant to reduce drusen
formation; Fenretinide (Sirion) as an antineoplastic to reduce lip-
ofuscin accumulation; Anecortave acetate (Alcon) as an angiostatic
agent to suppress conversion of dry AMD towet AMD; CNTF (ciliary
neurotrophic factor;Neurotech) for atrophic macular degeneration;
POT-4 (Potentia) as a complement inhibitor to shut down the
complement activation system that leads to local inﬂammation;
Rapamycin (MacuSight) as an immune suppressant similar to
steroids as an anti-inﬂammatory agent; and AREDS-2 (NEI) as an
antioxidant.
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